A synthetically produced immunomodulator that stimulates the immune system's disease-fighting properties. Potential indications include the treatment of patients with hepatitis B and C; HIV/AIDS; cancer, including liver cancer, melanoma, non�small cell lung cancer, and colorectal cancer. Orphan drug designation for the treatment of hepatocellular carcinoma granted in March 2000. Approved in several overseas markets; investigational in the U.S. where clinical trials are underway related to the use of Zadaxin (1) in combination with interferon as treatment for hepatitis C; (2) as monotherapy or in combination with certain antiviral drugs as treatment for hepatitis B; (3) in combination with chemotherapy for the treatment of cancer; (4) in combination with radiofrequency ablation (RFA) and in combination with transarterial chemoembolization (TACE) for the treatment of hepatocellular carcinoma. Mfg: SciClone Pharmaceuticals, Inc. Source: PR Newswire - 11/12/96, 03/22/00, 01/08/01.
http://www.friedlnet.com/0108-047.html There is alot more Money to be made in China for HBV IMHO!Higher dose Zadaxin plus Lamivudine may be the Ideal Combination.I have read that Northern China is heavily infected with HBeAg-Negative HBV.
This a firm thats been sucking its investors dry for like 14 years. Typically there are occasional bogus news releases that never materialize and new twists as to the firms direction with a drug named Zadaxin. Apparently selling to desperate third world countries that can't afford drug regulations. Management has stated they will not surrender any activity whatsoever to its retail shareholders, aside from the latest options grants to themselves. The average investor was in at approx. $6-8 per share. Currently an unexplained buying trend has left some with hope of recovering, how many bail after $8.50 is a major question.